Seres Therapeutics (MCRB) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research report sent to investors on Thursday. Zacks Investment Research currently has $6.25 price objective on the biotechnology company’s stock.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other research firms have also recently weighed in on MCRB. Oppenheimer set a $16.00 target price on shares of Seres Therapeutics and gave the company a buy rating in a research note on Friday, November 9th. Cantor Fitzgerald set a $15.00 target price on shares of Seres Therapeutics and gave the company a buy rating in a research note on Thursday, November 8th. BidaskClub upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research note on Saturday, November 10th. ValuEngine upgraded shares of Seres Therapeutics from a hold rating to a buy rating in a research note on Tuesday, November 6th. Finally, Chardan Capital restated a buy rating on shares of Seres Therapeutics in a research note on Sunday, October 28th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Seres Therapeutics currently has a consensus rating of Hold and a consensus price target of $13.06.

Shares of NASDAQ MCRB traded up $0.17 during mid-day trading on Thursday, hitting $6.38. The company had a trading volume of 73,200 shares, compared to its average volume of 98,175. Seres Therapeutics has a 12 month low of $4.42 and a 12 month high of $11.35. The stock has a market cap of $244.32 million, a PE ratio of -2.89 and a beta of 1.44.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. Seres Therapeutics had a negative net margin of 515.16% and a negative return on equity of 1,584.66%. The business had revenue of $9.06 million during the quarter, compared to analysts’ expectations of $23.43 million. On average, sell-side analysts predict that Seres Therapeutics will post -2.58 earnings per share for the current year.

In other Seres Therapeutics news, insider John G. Aunins sold 14,279 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $5.94, for a total transaction of $84,817.26. Following the completion of the transaction, the insider now owns 103,811 shares in the company, valued at $616,637.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider John G. Aunins sold 14,282 shares of the firm’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $6.39, for a total transaction of $91,261.98. Following the transaction, the insider now owns 75,250 shares of the company’s stock, valued at approximately $480,847.50. The disclosure for this sale can be found here. 37.10% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. lifted its stake in Seres Therapeutics by 18.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock worth $1,009,000 after purchasing an additional 18,562 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after buying an additional 25,287 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Seres Therapeutics by 23.0% during the second quarter. BlackRock Inc. now owns 2,240,844 shares of the biotechnology company’s stock worth $19,272,000 after buying an additional 418,589 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Seres Therapeutics by 100.6% during the second quarter. Millennium Management LLC now owns 172,173 shares of the biotechnology company’s stock worth $1,481,000 after buying an additional 86,348 shares in the last quarter. Finally, Jefferies Group LLC increased its holdings in shares of Seres Therapeutics by 75.5% during the third quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock worth $163,000 after buying an additional 9,215 shares in the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Story: The Structure of a Futures Contract

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply